Wilson Sonsini Goodrich & Rosati and Cooley advised Kura Oncology. Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised MARAbio Systems, Inc. on intellectual property matters related to the transaction. MARAbio Systems, Inc. (MARAbio), a precision immunology company whose...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised 858 Therapeutics on intellectual property matters related to the transaction. 858 Therapeutics announced raising $50 million in a Series B...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Autobahn Therapeutics on the transaction. Autobahn Therapeutics, a biotechnology company, announced the closing of an oversubscribed $100 million Series C...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Venatorx on IP matters in the transaction. Melinta Therapeutics LLC (Melinta) and Venatorx Pharmaceuticals, Inc. (Venatorx), announced that they have...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Seal Rock on the transaction. Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, has...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ventyx on the deal. Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal. Taylor Wessing advised Oppilan Pharma Limited and Zomagen Biosciences Limited. Ventyx Biosciences, a clinical-stage biotechnology...
You must be a Standard 1 Year member to access this content.
